$1.59 Billion is the total value of Sofinnova Investments, Inc.'s 186 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 138.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Amgen Incput | $39,743,000 | – | 168,500 | +100.0% | 2.50% | – | |
| UTHR | Buy | United Therapeutics Corp | $36,852,000 | +66.4% | 304,562 | +30.4% | 2.32% | +13.4% |
| AKUS | New | Akouos, Incadr | $34,089,000 | – | 1,515,073 | +100.0% | 2.15% | – |
| GILD | New | Gilead Sciences Inc | $31,045,000 | – | 403,494 | +100.0% | 1.96% | – |
| JAZZ | New | Jazz Pharmaceuticals PLC | $26,851,000 | – | 243,353 | +100.0% | 1.69% | – |
| ABBV | Buy | Abbvie Inc | $24,738,000 | +549.3% | 251,959 | +403.9% | 1.56% | +343.2% |
| LLY | New | Eli Lilly & Co | $24,446,000 | – | 148,900 | +100.0% | 1.54% | – |
| PTCT | Buy | PTC Therapeutics Inc | $22,239,000 | +70.6% | 438,270 | +50.0% | 1.40% | +16.3% |
| Buy | Alnylam Pharmaceuticals Inccall | $22,217,000 | +653.4% | 150,000 | +453.5% | 1.40% | +413.2% | |
| XLRN | Buy | Acceleron Pharma Inc | $20,710,000 | +39.5% | 217,390 | +31.6% | 1.31% | -4.9% |
| New | SPDR Ser Trput | $16,792,000 | – | 150,000 | +100.0% | 1.06% | – | |
| New | SPDR Ser Trput | $15,011,000 | – | 150,000 | +100.0% | 0.95% | – | |
| HZNP | New | Horizon Therapeutics PLC | $14,059,000 | – | 252,958 | +100.0% | 0.89% | – |
| TGTX | Buy | TG Therapeutics Inc | $13,566,000 | +400.8% | 696,390 | +153.0% | 0.86% | +240.6% |
| INSM | New | Insmed Inc | $13,328,000 | – | 483,967 | +100.0% | 0.84% | – |
| New | Nucana Biomed Ltdordinary shares | $12,984,000 | – | 2,400,000 | +100.0% | 0.82% | – | |
| PBYI | Buy | Puma Biotechnology Inc | $12,491,000 | +132.0% | 1,197,630 | +87.7% | 0.79% | +58.0% |
| SUPN | New | Supernus Pharmaceuticals Inc | $11,359,000 | – | 478,329 | +100.0% | 0.72% | – |
| ZYME | Buy | Zymeworks Inc | $10,812,000 | +509.5% | 299,734 | +499.6% | 0.68% | +315.9% |
| MIRM | Buy | Mirum Pharmaceuticals Inc | $10,541,000 | +79.9% | 541,701 | +29.4% | 0.66% | +22.7% |
| New | iShares Trput | $10,023,000 | – | 70,000 | +100.0% | 0.63% | – | |
| KURA | New | Kura Oncology Inc | $9,959,000 | – | 610,979 | +100.0% | 0.63% | – |
| AKBA | New | Akebia Therapeutics Inc | $9,261,000 | – | 681,892 | +100.0% | 0.58% | – |
| KDMN | Buy | Kadmon Holdings Inc | $7,838,000 | +22.6% | 1,530,864 | +0.3% | 0.49% | -16.6% |
| New | Invesco QQQ Trustput | $7,428,000 | – | 30,000 | +100.0% | 0.47% | – | |
| BPMC | Buy | Blueprint Medicines Corp | $7,401,000 | +100.6% | 94,891 | +50.4% | 0.47% | +37.0% |
| AXSM | Buy | Axsome Therapeutics Inc | $7,156,000 | +66.3% | 86,978 | +18.9% | 0.45% | +13.3% |
| LQDA | New | Liquidia Technologies Inc | $6,736,000 | – | 800,000 | +100.0% | 0.42% | – |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $6,470,000 | +296.4% | 1,357,848 | +66.5% | 0.41% | +170.2% |
| AGTC | Buy | Applied Genetic Technologies Corp | $6,345,000 | +82.1% | 1,145,254 | +7.8% | 0.40% | +24.2% |
| CNST | New | Constellation Pharmaceuticals Inc | $6,223,000 | – | 207,087 | +100.0% | 0.39% | – |
| ITCI | Buy | Intra-Cellular Therapies Inc | $6,209,000 | +676.1% | 241,908 | +365.2% | 0.39% | +428.4% |
| OTIC | Buy | Otonomy Inc | $5,978,000 | +100.2% | 1,651,411 | +9.0% | 0.38% | +36.6% |
| PTGX | New | Protagonist Therapeutics Inc | $5,758,000 | – | 326,064 | +100.0% | 0.36% | – |
| New | Pfizer Inccall | $5,723,000 | – | 175,000 | +100.0% | 0.36% | – | |
| New | Intra-Cellular Therapies Incput | $5,647,000 | – | 220,000 | +100.0% | 0.36% | – | |
| CCXI | Buy | ChemoCentryx Inc | $5,577,000 | +108.1% | 96,916 | +45.3% | 0.35% | +41.9% |
| CALA | Buy | Calithera Biosciences Inc | $5,493,000 | +51.1% | 1,040,399 | +27.0% | 0.35% | +3.0% |
| FIXX | Buy | Homology Medicines Inc | $5,234,000 | +46.0% | 344,579 | +49.4% | 0.33% | -0.6% |
| CYTK | New | Cytokinetics Inc | $3,776,000 | – | 160,217 | +100.0% | 0.24% | – |
| Buy | PTC Therapeutics Inccall | $3,044,000 | +36.5% | 60,000 | +20.0% | 0.19% | -6.8% | |
| New | Novocure Ltdcall | $2,965,000 | – | 50,000 | +100.0% | 0.19% | – | |
| RETA | New | Reata Pharmaceuticals Inc | $2,034,000 | – | 13,035 | +100.0% | 0.13% | – |
| SNDX | New | Syndax Pharmaceuticals Inc | $1,363,000 | – | 91,964 | +100.0% | 0.09% | – |
| MNLO | Buy | Menlo Therapeutics Inc | $1,256,000 | -22.5% | 725,571 | +20.0% | 0.08% | -47.3% |
| NTLA | New | Intellia Therapeutics Inc | $1,209,000 | – | 57,500 | +100.0% | 0.08% | – |
| IMVT | New | Immunovant Inc | $987,000 | – | 40,513 | +100.0% | 0.06% | – |
| MRTX | New | Mirati Therapeutics Inc | $922,000 | – | 8,072 | +100.0% | 0.06% | – |
| ARNA | New | Arena Pharmaceuticals Inc | $877,000 | – | 13,929 | +100.0% | 0.06% | – |
| ORIC | New | Oric Pharmaceuticals Inc | $585,000 | – | 17,369 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.